Abstract
Aim: Study of CA 125 level in Ovarian Tumours at M.Y. Hospital, Indore.
Material and Method: The Study was conducted at M. Y. Hospital, Indore from duration between Nov 2017 to Nov 2018 with total no. of patients 55 whose samples are recieved in histopathological section. The detailed clinical history with relevant investigations were taken.
Result: In our study, ca125 level above 35 u/ml is found in 32 malignant tumours and 09 bengin tumour while ca125 level below 35 u/ml is found in 03 malignant tumours and 11 bengin tumours.
Conclusion: CA125 is a biomarker that has potential utility for the spectrum: risk, early detection, diagnosis, prognosis, monitoring and therapy.
Keywords: CA 125, Ovarian tumour
References
- Hogdall E: Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008, 20:4-8.
- Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87– 95. [PubMed: 11207821]
- Bischof P, Tseng L, Brioschi PA, Herrmann WL. Cancer antigen 125 is produced by human endometrial stromal cells. Hum Reprod 1986;1:423–426. [PubMed: 2437144]
- Vora S, Bhargav VL. Clinicopathological study of ovarian neoplasms. J Obstet Gynecol India.1969; 19(3):358-62.
- Bhuvanesh U, Logambal A. A study of ovarian tumours. J Obstet Gynecol India. 1978; 28(2):271-7.
- Bast RC, Klug TL, St John E. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
- Malkasian G, Knapp RC, Lavin PT, et at. Preoperative evaluation of serum CA-125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6.
Corresponding Author
Dr Khushboo Likhar
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v7i3.02
